Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL CITRATE PRESERVATIVE FREE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL CITRATE PRESERVATIVE FREE versus QDOLO.
FENTANYL CITRATE PRESERVATIVE FREE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic opioid agonist; primarily binds to mu-opioid receptors in the CNS, modulating nociceptive pathways and producing analgesia, sedation, and euphoria.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Initial: 50-100 mcg IV every 2-5 minutes as needed for pain. For anesthesia: 2-50 mcg/kg IV bolus, then 0.7-10 mcg/kg/hr infusion.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life is approximately 2–4 hours in healthy adults, but may be prolonged to 4–12 hours in elderly, critically ill, or obese patients due to increased volume of distribution and decreased clearance. Context: Duration of action after a single bolus is relatively short due to redistribution, but accumulation can occur with repeated doses or infusions, leading to prolonged effects.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism via CYP3A4, with approximately 75% of the dose excreted in urine as metabolites (primarily norfentanyl) and <10% as unchanged fentanyl. About 9% is excreted in feces. Minimal biliary excretion.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist